Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

Core Insights - Labcorp has announced an expanded collaboration with PathAI to deploy AISight® Dx, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations, aiming to enhance efficiency, collaboration, and patient care [1][2] Group 1: Technology and Implementation - AISight® Dx is a cloud-based technology that enables pathologists to view and manage slides digitally, utilizing AI to support key diagnostic processes [1][2] - The platform will facilitate fully digital workflows for case management, slide review, collaboration, and annotation, integrating AI-powered image analysis and secure storage [2] - Labcorp's deployment of AISight Dx is part of its commitment to modernize pathology through AI, aiming for faster and more consistent results for patients and providers [2][3] Group 2: Strategic Importance - The collaboration builds on Labcorp's strategic investment in PathAI made in 2019, which has evolved to include AI-driven clinical trial support and validation of novel AI-pathology solutions [3] - Labcorp's leadership in diagnostics positions it as an ideal partner for PathAI in the mission to modernize pathology through software and AI [3] Group 3: Company Overview - Labcorp is a global leader in laboratory services, providing insights that help healthcare professionals make informed decisions, with nearly 71,000 employees serving clients in approximately 100 countries [4] - The company supported over 85% of new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests globally [4]